TGM2 and irritable bowel syndrome: The serological pooled prevalence of anti tTG-IgA (11 studies with a sample size of 2901 IBS patients) and AGA-IgG (4 studies with a sample size of 926 IBS patients) were 5.35% (95% CI: 3.60-7.89) and 6.35% (95% CI: 2.05-18.03), respectively (Figure 2).